SanegeneBio, a clinical-stage biotechnology firm specializing in innovative RNAi therapeutics, has successfully closed its Series B financing round, securing over $110 million in new capital. This substantial funding is strategically earmarked to propel its leading clinical assets toward pivotal registrational studies and to fast-track its diverse development pipeline. The successful round highlights significant investor confidence in the company's proprietary technology and its potential to address complex global health challenges.
A Coalition of Global Investors
The financing was led by a well-known industrial investor, signaling strong industry validation, and attracted a formidable syndicate of global backers. Participation included an international sovereign wealth fund, Sino Biopharm, Legend Capital, and Vivo Capital, alongside a key strategic investment from pharmaceutical leader Eli Lilly and Company. The continued commitment from existing shareholders, including Qiming Venture Partners and Northern Light Venture Capital, further underscores the sustained belief in SanegeneBio's long-term growth trajectory.
Fueling a Robust Clinical Pipeline
This infusion of capital will be instrumental in advancing SanegeneBio's diversified portfolio, which already includes four experimental medicines in clinical trials. The company is focused on developing treatments for major unmet needs in autoimmune nephropathies, cardiovascular disease, metabolic disorders, and obesity. The funds will directly support the global expansion of ongoing studies and the initiation of new clinical programs, moving promising candidates toward late-stage development.
Pioneering Advanced RNAi Delivery
Central to SanegeneBio's innovative edge is its proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform, a cornerstone of its research and development efforts. This industry-leading technology enables the creation of highly targeted RNAi therapeutics capable of reaching both liver and challenging extrahepatic tissues with precision. This differentiated capability allows the company to pursue a broader range of diseases and develop potential first-in-class and best-in-class medicines.
A Strategic Vision for Global Impact
Dr. Weimin Wang, the company's Founder and Chief Executive Officer, hailed the financing as a significant milestone that validates the team's scientific strength and corporate vision. He reiterated the company's unwavering commitment to addressing unmet medical needs by continuously pushing the boundaries of RNAi technology. Looking ahead, the firm plans to leverage this support to advance its investigational medicines globally and bring more transformative programs into the clinic.
Positioned for Future Growth
Since its inception in 2021, SanegeneBio has rapidly established itself as a fully-integrated biotechnology company with R&D operations across Boston, Shanghai, and Suzhou. The company is led by a team of seasoned RNAi veterans who are executing a clear vision to develop blockbuster medicines for diverse therapeutic areas. This successful financing round provides the critical resources needed to scale its operations and solidify its position as a leader in the next generation of genetic medicine.
The completion of this oversubscribed Series B round marks a pivotal moment for SanegeneBio, equipping it with the financial strength to accelerate its ambitious clinical and technological goals. This robust backing from a premier group of global investors not only validates the potential of its LEAD™ platform but also significantly enhances its capacity to deliver transformative RNAi therapies. Ultimately, this progress brings the promise of innovative new treatments a crucial step closer for patients worldwide suffering from serious and chronic diseases.